Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)
NCT03500562 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3
Last updated 2021-09-01
Summary
Study is a non-interventional, prospective, multicenter post marketing surveillance study to determine the safety of daclatasvir based therapy
Conditions
- Chronic Hepatitis C
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-05-08
- Primary Completion
- 2019-03-29
- Completion
- 2019-03-29
Countries
- China
Study Locations
More Related Trials
-
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients
NCT02576314 ·Status: COMPLETED ·Phase: PHASE3
-
A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects
NCT00663208 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C
NCT04952207 ·Status: UNKNOWN
-
Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection
NCT01257204 ·Status: COMPLETED ·Phase: PHASE2
-
SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C
NCT04070235 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period
NCT02531269 ·Status: COMPLETED
-
Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus
NCT01628692 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
NCT02170727 ·Status: COMPLETED ·Phase: PHASE3
-
A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
NCT00546715 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects
NCT02583685 ·Status: COMPLETED ·Phase: PHASE2
-
Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)
NCT03887637 ·Status: UNKNOWN
-
Study of CTS-1027 in Hepatitis C Patients
NCT00570336 ·Status: COMPLETED ·Phase: PHASE2
-
An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C
NCT04301882 ·Status: UNKNOWN
-
Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes
NCT01226797 ·Status: TERMINATED ·Phase: PHASE2
-
Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual
NCT01995266 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C
NCT04071353 ·Status: UNKNOWN
-
Glecaprevir/Pibrentasvir Real-world Study in China
NCT03941821 ·Status: UNKNOWN
-
Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C
NCT02250001 ·Status: COMPLETED
-
A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)
NCT02556086 ·Status: WITHDRAWN ·Phase: PHASE2
-
Safety and Efficacy Study in Hepatitis C Patients With PHN121
NCT01052090 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject
NCT01051414 ·Status: COMPLETED ·Phase: PHASE2
-
SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients
NCT02473211 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
NCT02578693 ·Status: COMPLETED
-
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
NCT01492504 ·Status: COMPLETED
-
Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults
NCT03208322 ·Status: WITHDRAWN